Stifel 2025 Healthcare Conference November 12, 2025 Jay Duker, MD President and CEO © 2025 EyePoint. All Rights Reserved. Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, are fo ...

DURAVYU Clinical Trials and Data - DURAVYU pivotal Phase 3 trial in wet AMD, LUGANO is fully enrolled, and LUCIA is 60% enrolled and randomized[3] - VERONA Phase 2 trial in DME showed highly positive efficacy and safety data[3] - DAVIO 2 Phase 2 trial showed 89% reduction in treatment burden with 2mg DURAVYU and 85% with 3mg DURAVYU vs 6 months prior[29] - In the VERONA Phase 2 DME trial, DURAVYU 2.7mg demonstrated an early and sustained BCVA improvement of +7.1 letters and CST improvement of -76 microns[47] - In a sub-group analysis of supplement-free patients in the VERONA trial, DURAVYU 2.7mg showed a mean BCVA change from baseline of +7.3 letters and a CST change of -73.7 um[59] Market and Unmet Needs - Over 80% of Retina Specialists indicate undertreatment in wet AMD is due to patient noncompliance, scheduling limitations, or provider preference for less frequent dosing[8] - A delay in treatment of only 5.34 weeks can result in vision loss[9] - By 2030, the global branded market for DME is projected to reach $3.0 billion[11] - By 2050, diabetes-related vision loss is expected to cost $500 million annually in the US[12] Company Financials and Pipeline - EyePoint Pharmaceuticals had $318 million in cash as of March 31, 2025, providing a runway into 2027 post Phase 3 LUGANO/LUCIA data in 2026[3] - LUCIA full enrollment is anticipated in 3Q 2025[5] - LUGANO topline data is anticipated in mid-2026, with LUCIA topline data following in 2H 2026[35]

DURAVYU Program - DURAVYU, a patent-protected vorolanib product utilizing Durasert E technology, is in Phase 3 trials for wet AMD and has a program in DME supported by Phase 2 data[3] - Phase 2 VERONA trial in DME showed a 73% supplement-free rate in the 2.7mg DURAVYU arm compared to 50% in the aflibercept control group[35] - The VERONA trial's 2.7mg DURAVYU treatment demonstrated a clinically meaningful improvement in BCVA of +7.1 letters[35] - The VERONA trial's 2.7mg DURAVYU treatment demonstrated an early and sustained CST improvement of -76 microns[35] Clinical Trials and Pipeline - EyePoint is conducting two global Phase 3 non-inferiority pivotal trials (LUGANO and LUCIA) in wet AMD[3] - Enrollment completion in the EYP-2301 program for serious retinal diseases is expected in the second half of 2025[6] - LUGANO trial is ~1/3 enrolled, and LUCIA is exceeding expectations as of January 2025, with topline data for both Phase 3 pivotal trials anticipated in 2026[65, 66] Financial Status - EyePoint has a strong balance sheet with approximately $370 million in cash and equivalents as of December 31, 2024, providing a cash runway into 2027[3] Market Opportunity - The global market for DME is projected to reach $3.9 billion by 2030[25]